Study predicting response to pembrolizumab in advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks back at prior treatment to learn which patients with advanced non-small cell lung cancer (NSCLC) are more likely to respond to pembrolizumab, an immune therapy given up front. The results may help doctors better predict who benefits from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older).
- You have advanced non-small cell lung cancer (NSCLC).
- Your tumor test showed PD-L1 “TPS” of 50% or higher.
- You received your first pembrolizumab treatment between January 2017 and December 2019.
- You have not been treated with immunotherapy before pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) works better for people with advanced non-small cell lung cancer by looking at their immune system's T-cells (a type of white blood cell). The goal is to understand which patients benefit most, which could help guide more personalized treatment.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial is testing whether a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) is effective for people with advanced non-small cell lung cancer. If you haven't had treatment yet and meet the health criteria, this study could offer a new option to control your cancer.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.